A detailed history of Logos Global Management LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Logos Global Management LP holds 150,000 shares of SRPT stock, worth $17.8 Million. This represents 2.48% of its overall portfolio holdings.

Number of Shares
150,000
Previous 150,000 -0.0%
Holding current value
$17.8 Million
Previous $23.7 Million 20.95%
% of portfolio
2.48%
Previous 2.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$113.33 - $163.85 $28.3 Million - $41 Million
-250,000 Reduced 62.5%
150,000 $23.7 Million
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $37.5 Million - $56.6 Million
400,000 New
400,000 $51.8 Million
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $10.3 Million - $12.4 Million
-100,000 Reduced 33.33%
200,000 $24.2 Million
Q2 2023

Aug 14, 2023

BUY
$106.4 - $157.19 $8.51 Million - $12.6 Million
80,000 Added 36.36%
300,000 $34.4 Million
Q4 2022

Feb 14, 2023

SELL
$100.86 - $132.13 $13.1 Million - $17.2 Million
-130,000 Reduced 37.14%
220,000 $28.5 Million
Q3 2022

Nov 14, 2022

SELL
$75.71 - $119.24 $3.79 Million - $5.96 Million
-50,000 Reduced 12.5%
350,000 $38.7 Million
Q2 2022

Aug 15, 2022

BUY
$62.69 - $88.44 $25.1 Million - $35.4 Million
400,000 New
400,000 $30 Million
Q4 2020

Feb 16, 2021

SELL
$125.56 - $178.74 $34.5 Million - $49.2 Million
-275,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$127.12 - $172.34 $35 Million - $47.4 Million
275,000 New
275,000 $38.6 Million
Q2 2020

Aug 14, 2020

SELL
$93.0 - $171.7 $17.4 Million - $32.2 Million
-187,350 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$82.38 - $131.64 $3.18 Million - $5.09 Million
-38,652 Reduced 17.1%
187,350 $18.3 Million
Q4 2019

Feb 14, 2020

BUY
$76.53 - $135.58 $17.3 Million - $30.6 Million
226,002 New
226,002 $29.2 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Logos Global Management LP Portfolio

Follow Logos Global Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.